Inflation is back in the spotlight as investors brace for the July CPI report, fresh earnings and an uncertain Federal Reserve path. With markets swinging between optimism over falling oil prices and concern about what comes next for rates, reliable dividend income can feel more valuable than ever. This article looks at three large dividend stocks from our inflation resilient screener that appear closely tied to these macro shocks.

The three stocks that follow are only a starting sample, since the full screen surfaced 24 more companies with equally compelling dividend and balance sheet stories that are not covered here.

To size up that wider opportunity set in a consistent way, head straight into the Inflation-Resilient Dividend Stocks screener to identify, filter and analyze the ideas that best fit your income and inflation views.

Abbott Laboratories (ABT)

Abbott Laboratories is a global healthcare company that sells everything from generic medicines and diagnostics to nutrition brands and medical devices used to manage heart disease and diabetes. It generates most of its revenue from Medical Devices at about US$22.5b, followed by Diagnostic Products at roughly US$10.0b, Nutritional Products at about US$8.3b and Established Pharmaceuticals at around US$5.8b, with only a small contribution from other activities. The company is large in scale with a market cap of roughly US$186.8b.

Investors looking for inflation resilient income tend to pay attention to Abbott Laboratories because it combines a long dividend track record with exposure to areas like diagnostics, diabetes care and cardiovascular devices that often see steady demand regardless of the economic cycle. Recent quarterly results beat expectations, guidance was raised and new products such as Libre Duo sensors and cancer diagnostics are building out higher margin franchises. At the same time, margin pressure, a rich P/E multiple and higher debt after the Exact Sciences acquisition mean you are paying for that quality and growth potential. The real question is whether Abbott’s shifting mix toward MedTech and specialized diagnostics justifies that premium over the long run.

Abbott’s premium P/E and its push into higher margin MedTech make the simple dividend story look incomplete. Get the full picture with the 3 key rewards and 2 important warning signs that could explain what the market is really pricing in.

Build your own inflation resilient dividend shortlist

Abbott Laboratories and the other dividend stocks in this article all surfaced using a few simple screener filters. Put those ideas to work by using our Screener to blend valuation, dividend strength, balance sheet quality and risk checks, or jump straight into our curated Investing Ideas for ready made shortlists that match different investing styles.

Allegion (ALLE)

Allegion is a global security products company best known for locks, access control systems and door hardware used across schools, hospitals, offices and homes. It generates most of its revenue in Allegion Americas, which brings in about US$3.4b each year, with Allegion International contributing roughly US$921 million. The company is mid sized with a market cap of about US$14.3b.

For income investors watching inflation, Allegion offers a mix of pricing power, dividend habit and a business tied to physical security rather than discretionary spending. Earnings have grown steadily, margins are healthy and returns on equity are high, helped recently by strong Americas demand and cost savings that supported the latest guidance upgrade. The picture is not all one way though. High debt, recent insider selling and slower expected growth than the broader US market mean this is not a simple “set and forget” dividend story. This is exactly why it deserves a closer look.

Allegion’s strong margins and high returns on equity could be masking a more complicated security story. Get the full 4 key rewards and 2 important warning signs before those “steady” dividends start to look more cyclical than they seem.

Hikma Pharmaceuticals (LSE:HIK)

Hikma Pharmaceuticals is a global drug manufacturer that focuses on generic, specialty and branded medicines across key areas such as respiratory, oncology and pain management, supplying hospitals and retail pharmacies in regions including the UK, Europe, North America and MENA. It produces tablets, liquids and injectable products that slot directly into everyday healthcare systems rather than discretionary spending, which can appeal to investors watching inflation. Hikma Pharmaceuticals currently has a market cap of about £3.5b.

Hikma Pharmaceuticals stands out in an inflation focused dividend search because it combines a 3.71% yield with a broad portfolio in essential medicines and injectables, steady MENA branded operations and a growing US manufacturing footprint backed by a planned $267 million investment in Ohio facilities. Some analysts forecast earnings growth while the stock trades well below certain fair value estimates. However, high debt, only modestly covered dividends and recent product recalls keep risk firmly on the table. With fresh buybacks, a supportive legal ruling in the Amarin case and a more acquisition hungry CEO, this is a company where resilient sector exposure exists alongside meaningful execution and regulatory questions that investors will want to weigh carefully.

Hikma Pharmaceuticals looks like an income story that could be quietly changing gears, with essential drugs, fresh buybacks and a new CEO reshaping the risk reward mix. Get the full full narrative for Hikma Pharmaceuticals

Curious About High Conviction Alternatives

Fresh ideas do not stay under the radar for long. New momentum can turn into a breakout before the crowd catches it. Scan these focused stock lists and consider whether they fit your strategy.

• Spot companies building real staying power by running the list of solid balance sheet and fundamentals (49 results) while it still highlights balance sheets and fundamentals that others may overlook.
• Review themes that could be gathering momentum by checking the 89 nuclear energy infrastructure stocks before the crowd notices how these projects reshape energy infrastructure.
• Identify businesses where automation is already driving results by using the 36 robotics and automation stocks while these opportunities remain under the radar for now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.